Regulatory Compliance

London – – September 30, 2026 -- RBC Capital Markets has been awarded General Clearing Member (GCM) status by European Commodity Clearing AG (ECC), enabling the bank to clear and settle transactions on behalf of Non-Clearing Members across Europe's energy and commodity markets.

RBC gains authorization to clear power, gas and carbon products via EEX

As a General Clearing Member, RBC Capital Markets can now offer a full suite of clearing services covering power and gas futures and spot contracts, European Energy Exchange (EEX) carbon auctions, and a broader range of products across the wider EEX platform.

The status extends the bank's clearing reach to clients that include some of Europe's largest energy producers, utilities and financial institutions, according to the company.

Lisbon – September 30, 2026 -- SOFTSWISS has released its 2027 iGaming Trends report, drawing on a survey of more than 500 industry experts and analysis of over 480,000 media headlines to map the sector's regulatory, technological and competitive trajectory.

Fifth anniversary edition adds cross-sector benchmarking against e-commerce and crypto

Marking five years of publication, this edition introduces a new "Beyond iGaming" framework comparing the industry against e-commerce, sports, film, gaming, streaming, e-pharma and crypto on metrics including market size, growth rate, regulatory maturity and digital adoption.

London – September 30, 2026 -- A new global study from Everpure (NYSE: P) finds that 64% of enterprises operate without a formal data sovereignty strategy, even as 88% of large-enterprise C-suite leaders believe a sovereignty failure could cost them their job.

Executives fear financial and reputational fallout from sovereignty failures

The Global Data Sovereignty Report 2026, based on a Vanson Bourne survey of 2,100 C-suite and IT leaders across the UK, France, Germany, Australia, Japan, South Korea, Singapore and India in June 2026, found 91% of respondents worry about financial and reputational damage tied to sovereignty lapses. Ninety percent recognize data sovereignty as a core business concern.

Stockholm – September 30, 2026 -- Autoliv, Inc. has retired 1,232,671 shares of common stock repurchased during the third quarter, reducing its total issued shares to 74,421,702 as of September 30, 2026.

Outstanding shares now stand at 72,006,695 following the retirement

Each outstanding share carries one vote. The retirement lowers the total count of issued shares, a mechanical adjustment tied to Autoliv's ongoing buyback program.

Autoliv holds 2,415,007 shares in treasury with no voting rights

Under Delaware law, treasury shares carry no voting rights and no entitlement to participate in distributions. The company disclosed the change as required under the Swedish Financial Instruments Trading Act (lagen (1991:980) om handel med finansiella instrument), with the filing distributed on September 30, 2026, at 08:00 CET.

Autoliv trades on the New York Stock Exchange under ALV and on Nasdaq Stockholm under ALIVsdb.

Berlin – – September 30, 2026 -- TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an IVDR-approved in vitro diagnostic test that simultaneously screens newborns for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) in countries accepting the CE mark.

Single kit consolidates three critical newborn screening panels for hospital labs

The test runs on established LightCycler systems, giving private and academic hospital laboratories a ready-to-use solution that integrates into existing workflows without requiring new infrastructure investment.

San Antonio – September 30, 2026 -- NTT TechnoCross has secured Frost & Sullivan's 2026 Japanese Company of the Year Recognition in privileged access management for the third consecutive year, citing its unified governance platform for enterprise cybersecurity.

Frost & Sullivan cites unified governance across human and non-human identities

Frost & Sullivan's evaluation benchmarked NTT TechnoCross across strategy effectiveness and strategy execution, with the company excelling in both dimensions. Vivien Pua, Industry Principal at Frost & Sullivan, noted that the company's iDoperation platform brings privileged account governance, access control, monitoring, auditing, analytics, and just-in-time access capabilities into a single system, aligning with enterprise demand for dynamic access management beyond traditional account protection.

Los Angeles – – September 30, 2026 -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) has signed a non-binding term sheet to move its entire EAI robotics business into Nasdaq-listed AIxCrypto Holdings, Inc. (NASDAQ: AIXC), at a proposed valuation of approximately $200 million in an all-stock deal.

AIxC will rename itself FF EAI Robotics Ecosystem Inc. and swap its ticker to FFR effective September 30, 2026.

Jinan – – September 30, 2026 -- Niutech Technology Group Co., Ltd. (SSE STAR Market: 688309) completed a group restructuring on August 26, 2026, consolidating nearly 40 years of industrial continuous pyrolysis operations as tightening EU recycling rules drive new orders for its waste tire and plastics processing lines.

UK customer signs RMB 198 million order after evaluating global peers

A UK customer assessed Niutech's European and Chinese project references, benchmarked the company against competitors worldwide, and signed an order worth RMB 198 million for chemical recycling equipment. The company frames the deal as capital-backed validation of its technology maturity in international waste plastic recycling.

Los Angeles – September 30, 2026 -- The California Consortium of Addiction Programs and Professionals (CCAPP) will run its 13th Annual California Addiction Conference (CAC) from October 14-18, 2026, at the Sheraton Universal Hotel in Universal City, consolidating three previously separate summits into a single five-day program.

Washington – September 30, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) reported positive topline results from a pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD), setting up a supplemental New Drug Application (sNDA) filing with the U.S. Food and Drug Administration (FDA).

Trial meets primary endpoint with statistically significant sleep-timing shift

The study, VP-VEC-162-3502 (NCT04652882), shifted sleep onset 42.5 minutes earlier in the HETLIOZ® arm (n=20) versus 5.4 minutes on placebo (n=20), a 37.1-minute difference (p=0.022). In an exploratory responder analysis, 60% of tasimelteon-treated participants (12/20) advanced sleep onset by at least 30 minutes, compared with 15% on placebo (3/20) (p=0.008).